Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 14c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.48), $0.14 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $64.9 million versus the consensus estimate of $71.84 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Boeing lands two U.S. defense contracts worth over $711M